CN113651873B - 肽组合物和使用方法 - Google Patents

肽组合物和使用方法

Info

Publication number
CN113651873B
CN113651873B CN202110665678.1A CN202110665678A CN113651873B CN 113651873 B CN113651873 B CN 113651873B CN 202110665678 A CN202110665678 A CN 202110665678A CN 113651873 B CN113651873 B CN 113651873B
Authority
CN
China
Prior art keywords
compound
retinal
pharmaceutical composition
composition
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110665678.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN113651873A (zh
Inventor
C.G.贝西尔利
A.J.布里奇斯
J.K.弗雷施利
W.A.亨克
L.L.约翰逊
F.X.史密斯
E.西尔万
D.N.扎克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan Ann Arbor
ONL Therapeutics Inc
Original Assignee
University of Michigan Ann Arbor
ONL Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan Ann Arbor, ONL Therapeutics Inc filed Critical University of Michigan Ann Arbor
Publication of CN113651873A publication Critical patent/CN113651873A/zh
Application granted granted Critical
Publication of CN113651873B publication Critical patent/CN113651873B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202110665678.1A 2015-05-01 2016-04-29 肽组合物和使用方法 Active CN113651873B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562155711P 2015-05-01 2015-05-01
US62/155,711 2015-05-01
CN201680038258.8A CN107708416B (zh) 2015-05-01 2016-04-29 肽组合物和使用方法
PCT/US2016/030098 WO2016178993A1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680038258.8A Division CN107708416B (zh) 2015-05-01 2016-04-29 肽组合物和使用方法

Publications (2)

Publication Number Publication Date
CN113651873A CN113651873A (zh) 2021-11-16
CN113651873B true CN113651873B (zh) 2025-09-02

Family

ID=57217771

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110665678.1A Active CN113651873B (zh) 2015-05-01 2016-04-29 肽组合物和使用方法
CN201680038258.8A Active CN107708416B (zh) 2015-05-01 2016-04-29 肽组合物和使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680038258.8A Active CN107708416B (zh) 2015-05-01 2016-04-29 肽组合物和使用方法

Country Status (21)

Country Link
US (5) US10508134B2 (https=)
EP (3) EP4623925A3 (https=)
JP (2) JP6884755B2 (https=)
KR (2) KR20240046280A (https=)
CN (2) CN113651873B (https=)
AU (1) AU2016258837B2 (https=)
CA (1) CA2984154A1 (https=)
CY (1) CY1124911T1 (https=)
DK (1) DK3288379T3 (https=)
EA (2) EA035293B1 (https=)
ES (1) ES2906173T3 (https=)
HR (1) HRP20220138T1 (https=)
HU (1) HUE057883T2 (https=)
LT (1) LT3288379T (https=)
MX (1) MX387317B (https=)
PL (1) PL3288379T3 (https=)
PT (1) PT3288379T (https=)
RS (1) RS62866B1 (https=)
SI (1) SI3288379T1 (https=)
SM (1) SMT202200069T1 (https=)
WO (1) WO2016178993A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10508134B2 (en) 2015-05-01 2019-12-17 Onl Therapeutics, Inc. Peptide compositions and methods of use
EP3768301A4 (en) * 2018-03-20 2022-06-08 ONL Therapeutics, Inc. COMPOSITIONS AND METHODS FOR FAS INHIBITION
CN112566622A (zh) * 2018-06-19 2021-03-26 细胞疗法有限责任公司 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统
US20230094423A1 (en) * 2019-12-18 2023-03-30 Cella Therapeutics, Llc Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (fas) or fas ligand (fasl) inhibitor, a tumor necrosis factor-alpha (tnf-alpha) or tnf receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitor
EP4355349A4 (en) * 2021-06-15 2025-04-16 ONL Therapeutics, Inc. Methods and compositions for treating eye diseases and disorders
AU2022311780A1 (en) * 2021-07-13 2024-02-08 Onl Therapeutics, Inc. Methods and compositions for improving visual function in ocular diseases and disorders
EP4456908A4 (en) * 2021-12-27 2025-08-27 Onl Therapeutics Inc SFASL TO INHIBIT RPE CELL DEATH AND ASSOCIATED DISORDERS
EP4565596A1 (en) * 2022-08-05 2025-06-11 ONL Therapeutics, Inc. Peptide compositions and methods of use
EP4565595A2 (en) * 2022-08-05 2025-06-11 ONL Therapeutics, Inc. Peptide compositions and methods of use
EP4698204A1 (en) * 2023-04-19 2026-02-25 ONL Therapeutics, Inc. Methods and compositions for treating rnfl thinning

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107708416A (zh) * 2015-05-01 2018-02-16 Onl医疗股份有限公司 肽组合物和使用方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5532123A (en) * 1990-07-11 1996-07-02 New York University Receptor-type phosphotyrosine phosphatase-γ
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
JP3187201B2 (ja) * 1992-05-14 2001-07-11 三共株式会社 Ｃ末端にプロリンアミドを有するペプチドの製法
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
JP3460863B2 (ja) 1993-09-17 2003-10-27 三菱電機株式会社 半導体装置の製造方法
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US6001962A (en) * 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US6363020B1 (en) 1999-12-06 2002-03-26 Virage Logic Corp. Architecture with multi-instance redundancy implementation
US6480428B2 (en) 2000-12-19 2002-11-12 Winbond Electronics Corporation Redundant circuit for memory device
CA2561809A1 (en) * 2004-03-31 2005-10-20 Xencor, Inc. Bmp-7 variants with improved properties
EP1737483A2 (en) 2004-04-23 2007-01-03 University of Pittsburgh of the Commonwealth System of Higher Education Cell death modulation via antagonists of fasl and fas activation
BRPI0609227A2 (pt) * 2005-05-10 2010-03-09 Alcon Inc composições de suspensão de nepafenac e outros fármacos oftálmicos, bem como uso das referidas composições no tratamento tópico de distúrbios oftálmicos
JP2009514969A (ja) * 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
EP1963364A2 (en) * 2005-12-01 2008-09-03 University of Pittsburgh - Of the Commonwealth System of Higher Education Compounds and methods for inhibiting apoptosis
JP5529754B2 (ja) * 2007-12-21 2014-06-25 ストライカー コーポレイション Ｎｏｇｇｉｎに対する感受性が低下したＢＭＰ変異体
WO2010102052A2 (en) * 2009-03-03 2010-09-10 The Regents Of The University Of Michigan Methods of inhibiting photoreceptor apoptosis
WO2010113753A1 (ja) * 2009-03-30 2010-10-07 参天製薬株式会社 ＪＮＫ（ｃ－Ｊｕｎアミノ末端キナーゼ）阻害ペプチドを用いた網膜疾患の予防または治療剤、網膜疾患の予防または治療方法、ならびに、その使用
CN102574822A (zh) * 2009-08-04 2012-07-11 阿米拉制药公司 作为溶血磷脂酸受体拮抗剂的化合物
US8865881B2 (en) 2011-02-22 2014-10-21 California Institute Of Technology Delivery of proteins using adeno-associated virus (AAV) vectors
SG195302A1 (en) * 2011-06-06 2013-12-30 Kineta One Llc Shk-based pharmaceutical compositions and methods of manufacturing and using the same
WO2013106909A1 (en) 2012-01-18 2013-07-25 Governing Council Of The University Of Toronto Novel peptides and methods and uses thereof for preventing retinal disorders
JP6087429B2 (ja) * 2012-06-21 2017-03-01 ハノル バイオファーマ カンパニー リミテッドＨａｎａｌｌ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． 変形されたヒト腫瘍壊死因子受容体−１ポリペプチドの新規用途
US20150265679A1 (en) * 2012-11-02 2015-09-24 The United States Of America, As Represented By Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor
US20180024145A1 (en) 2015-02-05 2018-01-25 Immunarray USA, Inc. Methods and compositions for diagnosing brain injury or neurodegeneration
US20190201500A1 (en) 2015-05-01 2019-07-04 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
JP7493334B2 (ja) 2016-07-05 2024-05-31 ユニバーシティ オブ マサチューセッツ 緑内障における神経保護療法としてのｓＦａｓＬのＡＡＶ２媒介遺伝子送達
AR112257A1 (es) 2017-06-21 2019-10-09 Gilead Sciences Inc Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos
EP3768301A4 (en) 2018-03-20 2022-06-08 ONL Therapeutics, Inc. COMPOSITIONS AND METHODS FOR FAS INHIBITION
CN112566622A (zh) 2018-06-19 2021-03-26 细胞疗法有限责任公司 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107708416A (zh) * 2015-05-01 2018-02-16 Onl医疗股份有限公司 肽组合物和使用方法

Also Published As

Publication number Publication date
US11597749B2 (en) 2023-03-07
AU2016258837B2 (en) 2020-12-03
EP4623925A3 (en) 2026-02-11
CA2984154A1 (en) 2016-11-10
EP3288379B1 (en) 2021-11-03
JP2021120400A (ja) 2021-08-19
DK3288379T3 (da) 2022-02-07
EP3997981A1 (en) 2022-05-18
KR20240046280A (ko) 2024-04-08
EP3288379A1 (en) 2018-03-07
EP4623925A2 (en) 2025-10-01
CY1124911T1 (el) 2023-01-05
US12258425B2 (en) 2025-03-25
CN107708416B (zh) 2021-06-29
US10829518B2 (en) 2020-11-10
MX387317B (es) 2025-03-18
JP6884755B2 (ja) 2021-06-09
US20210094985A1 (en) 2021-04-01
EA035293B1 (ru) 2020-05-26
HRP20220138T1 (hr) 2022-05-27
HUE057883T2 (hu) 2022-06-28
WO2016178993A1 (en) 2016-11-10
US20250346631A1 (en) 2025-11-13
EA202090184A3 (ru) 2020-07-31
AU2016258837A1 (en) 2017-11-09
EP3288379A4 (en) 2018-10-24
JP2018514590A (ja) 2018-06-07
PL3288379T3 (pl) 2022-03-07
SMT202200069T1 (it) 2022-03-21
CN113651873A (zh) 2021-11-16
RS62866B1 (sr) 2022-02-28
US20230287052A1 (en) 2023-09-14
MX2017014075A (es) 2018-07-06
KR20170140383A (ko) 2017-12-20
ES2906173T3 (es) 2022-04-13
BR112017023479A2 (pt) 2018-07-24
CN107708416A (zh) 2018-02-16
KR102652804B1 (ko) 2024-04-01
LT3288379T (lt) 2022-02-25
US20200123201A1 (en) 2020-04-23
US20180291062A1 (en) 2018-10-11
SI3288379T1 (sl) 2022-06-30
PT3288379T (pt) 2022-02-08
HK1251979A1 (zh) 2019-05-10
EA202090184A2 (ru) 2020-05-31
US10508134B2 (en) 2019-12-17
EA201792399A1 (ru) 2018-05-31

Similar Documents

Publication Publication Date Title
US12258425B2 (en) Peptide compositions and methods of use
US20130190278A1 (en) Compounds for the Treatment/Prevention of Ocular Inflammatory Diseases
CA3054290A1 (en) Stable peptide compositions
ES2863701T3 (es) Inhibidores de la dipeptidil peptidasa-4 para el tratamiento tópico ocular de enfermedades neurodegenerativas de la retina
US20190201500A1 (en) Compositions and methods of fas inhibition
US20240058265A1 (en) Treatment of ocular diseases using endothelin receptor antagonists
KR102023827B1 (ko) 안구 건조증 질환의 치료 및/또는 예방을 위한 짧은 합성 펩티드의 용도
HK1251979B (en) Peptide compositions and methods of use
US20200129585A1 (en) Adiponectin peptidomimetics formulations
BR112017023479B1 (pt) Composto, composição e uso de um composto ou composição
WO2025133214A1 (en) Ophthalmic polypeptide compositions for the treatment of posterior eye disorders
EP4475866A1 (en) Peptides and methods of use thereof in treating ocular disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant